ResMed (RMD) Reports Q1 EPS of $0.52, Beats by 6c
More News related to RMD
- Notable Analyst Rating Changes 11/06: GE, CBS, HD/LOW, M Upgrade; ESLR, RMD, SUN Downgrade
- Morgan Stanley Downgrades ResMed (RMD) to Equalweight
- Jefferies & Co Downgrades ResMed (RMD) to Hold
- ResMed (RMD) Tops Q3 Views
- ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
More News related to Earnings
- Pritchard Capital Initiates Coverage on Construction Services Stocks
- Sidoti & Co Initiates Coverage on Scholastic (SCHL) with a Buy
- Raymond James Initiates Coverage on Movie Production, Theater Stocks
- C. K. Cooper & Company Initiates Coverage on Atwood Oceanics (ATW) with a Buy
- Macquarie Initiates Coverage on Comverge (COMV) with an Outperform
ResMed Inc. (NYSE: RMD) reports Q1 EPS of $0.52, 6 cents better than the analyst estimate of $0.46. Revenue for the quarter was $227.9 million, versus the consensus of $227.66 million.
Related Categories
EarningsStocks Mentioned
+0.80Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
